Exploring variations in weight loss based on sex, race, concomitant therapies, altered microbiota, and genetic background is essential
Nevertheless, the biologic agent used in Ozempic is semaglutide, it controls the amount of blood glucose and also leads to weight loss as concluded by the trials
In patients with mild renal impairment, as per the European labeling, dose adjustment for GLP-1 RAs is not needed, but some cannot be used or are not recommended in patients with severe renal impairment and end-stage disease [12], with exceptions such as dulaglutide, liraglutide, and semaglutide, which can be used in severe renal impairment but not end-stage renal disease
Molecular Biology and Evolution
1:500) or mouse anti-DNA (Progen, 61014